RadNet, Inc. (RDNT) is a Los Angeles-based provider of outpatient diagnostic imaging — MRI, CT, PET, mammography, and ultrasound — operating across its Imaging Centers and Digital Health segments. To establish a central target, six current, individually attributable analyst targets were reviewed: Barclays (Andrew Mok) at $79, B. Riley Securities (Yuan Zhi) at $83, KeyBanc (Matthew Gillmor) at $92, Truist (David Macdonald) at $94, Raymond James (John Ransom) at $95, and Jefferies at $96. The arithmetic mean is approximately $89.83, rounded to a clean $90 central target.
The low-to-high range of $79 to $96 is relatively tight for a growth story but still reveals real disagreement. The more cautious view, led by Barclays' $79, implies that much of the AI opportunity is not yet reflected in near-term earnings and that the stock's valuation already prices in significant execution. The more constructive view, from Truist, Raymond James, and Jefferies in the mid-$90s, credits RadNet's scale, demand tailwinds, and increasingly integrated digital offerings. Recent actions have been broadly positive: Truist lifted its target to $94 from $90 after second-quarter results, while Raymond James reiterated its Strong Buy and $95 target even after a short-seller report questioned the AI segment and accounting practices.
In early November 2026, RDNT traded near $79–$80, below its 52-week high of about $85.84 but well above its 52-week low near $50.82. Reaching $90 from $79–$80 implies roughly 13% to 14% upside — a modest move by the standards of an earlier-stage healthcare growth name, yet one that still requires the market to reward continued revenue expansion and margin progress rather than simply holding current levels.
The path runs through fundamentals. Trailing revenue is approximately $2.38 billion, up about 21% year over year, but the company reported a net loss on a trailing basis, and its forward P/E (price-to-earnings ratio) sits in the triple digits. That means the stock is not a valuation bargain; it is a bet on the compounding of imaging volumes and the monetization of AI-driven workflow and screening tools. Supporting that case, management has emphasized broad capabilities and interconnected offerings at its investor day, and analysts raised targets through late 2026 on that narrative.
The stock has been in a broad uptrend, trading above both its 50-day and 200-day moving averages. The most relevant overhead marker is the 52-week high near $85.84, which sits between the current price and the $90 target and would likely act as an initial resistance zone. On the downside, the $72–$73 area, a level where shares consolidated in early November, offers nearby support, with the 50-day average in the low-$70s as a secondary reference. A sustained move toward $90 would plausibly require clearing the prior high first.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms apply different methodologies and the underlying targets here were issued at different dates across 2026. Investors should monitor quarterly earnings and guidance — particularly margin trends and any update on Digital Health and AI revenue — along with reimbursement developments, analyst target revisions, and responses to the short-seller scrutiny. Any sign that revenue growth is decelerating or that the AI segment's economics are falling short of expectations would matter most for the path toward $90.
For traders seeking a more dynamic view, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning alone. Exploring these signals alongside fundamental research can add a timely, data-driven layer to the decision-making process.
The $90 central target for RadNet is the rounded mean of six verified analyst price targets, ranging from $79 to $96, and it requires a modest advance of roughly 13% to 14% from recent prices near $79–$80. The bull case leans on a dominant outpatient imaging footprint, double-digit revenue growth, and an emerging AI franchise, while the bear case centers on reimbursement risk, unproven AI economics, and a premium valuation with no trailing profitability. The spread between the low-$80s and mid-$90s targets shows that analysts genuinely disagree about how quickly — and how credibly — RadNet can convert growth into earnings. Whether the stock approaches $90 will likely depend less on any single catalyst and more on sustained margin execution, continued analyst revisions, and how the market weighs the AI narrative over the coming quarters.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RDNT has been loosely correlated with ITGR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RDNT jumps, then ITGR could also see price increases.
| Ticker / NAME | Correlation To RDNT | 1D Price Change % | ||
|---|---|---|---|---|
| RDNT | 100% | -0.56% | ||
| ITGR - RDNT | 49% Loosely correlated | +0.05% | ||
| GKOS - RDNT | 48% Loosely correlated | -1.07% | ||
| NNOX - RDNT | 46% Loosely correlated | +59.80% | ||
| ICUI - RDNT | 43% Loosely correlated | +1.82% | ||
| CERS - RDNT | 42% Loosely correlated | -5.80% | ||
More | ||||